In late October, the UK Government announced a £55 billion commitment to research and development, led by the Department for Science, Innovation and Technology (DSIT). This funding, to be deployed through UKRI and related bodies over the coming years, is designed to accelerate innovation across health, clean energy, artificial intelligence, quantum technologies, and advanced manufacturing.
Crucially, this investment represents a direct government spending commitment , not a tax measure. Its objective is to stimulate innovation-led growth by funding R&D activity, strengthening national capabilities, and supporting the commercialisation of breakthrough technologies. At the same time, the primary fiscal mechanism supporting business-led innovation - R&D Tax Relief, administered separately by HMRC - is undergoing heightened scrutiny and regulatory tightening. While DSIT’s focus is on encouraging innovation at scale, HMRC’s mandate is to ensure compliance, prevent abuse, and protect public funds. Successfully navigating this landscape will depend on how well businesses structure their R&D activity, build robust evidence, and engage with the right expertise to access government support with confidence.
From 1 April 2024 , the government began implementing a unified approach that delivers relief predominantly through an above-the-line taxable credit . This change aims to simplify claims, increase transparency, and allow HMRC to more easily assess whether R&D activity delivers genuine commercial and economic impact. For businesses, the practical implications are significant; finance teams must be engaged earlier, and retrospective or poorly evidenced claims carry substantially higher risk. Increasingly, R&D tax relief is transitioning from a tactical tax benefit into a strategic financial and governance discipline.
Despite the scale of investment by the government and the stated ambition to drive economic growth through innovation, there is growing concern across the R&D community that policy intent and operational enforcement are not always aligned. Recent analysis from the Department for Science, Innovation and Technology (DSIT) rightly highlights how vital R&D tax relief is to the UK economy. However, the question remains whether DSIT and HMRC are fully aligned in how that ambition is translated into practice. HMRC’s Volume Compliance Approach, particularly within the ISBC unit, has had a chilling effect on legitimate claims, especially for innovative SMEs and early-stage businesses. For many start-ups and scale-ups, the resource required to respond to complex and often aggressive enquiry letters is simply unavailable. Combined with the challenges introduced by the Claim Notification Process and the reduction in SME relief rates, there is a real risk that valid R&D activity is left unsupported. This disconnects is crucial. If innovative businesses disengage from R&D tax relief due to perceived risk or uncertainty, the UK undermines the very outcomes this £55bn investment is designed to achieve. “R&D Tax Relief is under greater scrutiny than ever, particularly for innovative SMEs navigating the merged scheme, RDEC, and rising HMRC enquiries. Against this backdrop, the role of structured compliance and informed advisory support becomes critical; not just to protect claims, but to ensure innovation is not inadvertently stifled.” - Malcolm Henderson, Compliance Director at Bonham & Brook, Former HMRC R&D Unit Leader
At Bonham & Brook, we advise clients to treat R&D compliance as a growth enabler. With increasing scrutiny and evolving legislation, the ability to articulate your innovation story, clearly, credibly, and consistently, will determine your access to funding and your long-term competitiveness. To benefit from this £55bn government commitment, businesses must:
From 2026 and beyond, compliance will become the defining factor in successful R&D tax relief claims. Partnering with an experienced specialist R&D tax advisor will no longer be just an advantage, but an absolute necessity. Companies should start by reviewing their current R&D activities through the lens of commercial impact.
These questions are no longer optional; businesses need to be prepared.